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Abstract Dystrophin, a component of the muscle membrane 
cytoskeleton, is the protein altered in Duchenne Muscular 
Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). 
Dystrophin shares significant homology with other cytoskeletal 
proteins, such as oc-actinin and spectrin. On the basis of its 
sequence similarity with a-actinin and spectrin, dystrophin has 
been proposed to function as dimer. However, the existence of 
both dimers and monomers have been observed by electron 
microscopy. To address this apparent discrepancy, we expressed 
dystrophin fragments composed of different domains in an in 
vitro translation system. The expressed fragments were tested for 
their ability to interact with each other and full-length dystrophin 
by both immunoprecipitation and blot overlay assays. These 
assays were successfully used to demonstrate the dimerization of 
a-actinin and spectrin, yet failed to detect any interaction 
between dystrophin fragments. Although these in vitro results do 
not prove that dystrophin is not a dimer in vivo, they do indicate 
that this interaction is not like that of the a-actinin and spectrin. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Dystrophin is a large cytoskeletal protein found at the 
muscle sarcolemma and membrane specializations of some 
neurons [1,2]. Mutations of the gene encoding dystrophin 
have been shown to be causative for X-linked Duchenne Mus-
cular Dystrophy (DMD) and Becker Muscular Dystrophy 
(BMD) [3,4]. The 3685-amino-acid sequence shares homology 
with a large family of actin-binding cytoskeletal proteins that 
includes a-actinin and spectrin [5]. The functions of dystro-
phin are still emerging but, based on its subcellular localiza-
tion and homology with spectrin, it is thought to maintain the 
integrity of the muscle membrane and to protect myofibers 
from damage during contraction and relaxation [6]. 
Dystrophin contains four large structurally distinct domains 
[7]: an N-terminal actin-binding domain, an internal rod do-
main that contains 24 repeat units structurally homologous to 
those found in spectrin, a cysteine-rich region which has ho-
mology to EF-hand calcium-binding domain found in cal-
modulin, a-actinin and (3-spectrin, and, lastly, a unique car-
boxyl terminus that only shows sequence similarity to an 
autosomal 395 kDa dystrophin-related protein (DRP), utro-
phin [8], and the human homologue of the Torpedo 87 kDa 
post-synaptic membrane protein, dystrobrevin [9]. Recently, a 
motif that contains two highly conserved tryptophan residues 
known as WW domain has also been identified at the end of 
the rod domain [10]. 
Since both spectrins and a-actinin exist as anti-parallel 
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dimers [11,12], given its overall structural homology with 
them, dystrophin is also expected to function as a dimer. 
However, electron microscopy analyses of rotary-shadowed 
images of dystrophin have reported that the molecular shape 
of dystrophin to be either a 175 nm flexible rod monomer 
[13,14] or a 120 nm dumbbell-shaped dimer [15]. At this mo-
ment, there is no clear biochemical data to support or reject 
either finding. Meanwhile, in vivo analysis of dystrophin has 
been hindered by factors, such as its enormous size (427 kDa), 
low abundance in muscle (0.002%) and tight association with 
other dystrophin-associated proteins. 
Because of this difficulty, we examined the potential dimer-
ization of dystrophm by expressing different fragments of dys-
trophin in vitro and tested their ability to interact with each 
other in both immunoprecipitation and blot overlay assay. 
Muscle homogenates containing full-length dystrophin were 
also tested for their ability to interact with the in vitro trans-
lated dystrophin fragments in the overlay assay. In neither 
system could we detect association of any dystrophin frag-
ment with itself or other fragments. However, under the 
same conditions, we clearly documented the dimerization of 
a-actinins and spectrins. Our results suggest that the biochem-
ical properties of dystrophin are different from a-actinin and 
spectrin in spite of their significant structural homology. In 
addition, our findings support the electron microscopic studies 
that dystrophin is a monomer. 
2. Materials and methods 
2.1. Subcloning of dystrophin fragments into expression vectors 
PCR primers were designed to amplify regions of cDNA corre-
sponding to the different domains of dystrophin from the full-length 
dystrophin cDNA clone, BTFL [4]. To maintain the accuracy of the 
amplification, Expand® High Fidelity DNA polymerase which has a 
3'-5' exonuclease proofreading activity was used (Boehringer Mann-
heim, Germany). The 5' and 3' ends of each clone were sequenced by 
the dideoxy-termination method using Taq polymerase to confirm the 
accuracy of the cloning procedures. The constructs, along with their 
expressed dystrophin sequences and the PCR primers are listed in 
Table 1. 
2.2. In vitro translation of dystrophin sequences 
The expression vectors used in this study, pMGT-1 and pFHR-1, 
have been previously described in detail [16]. The pFHR-1 vector 
allowed the translation of the protein of interest with a N-terminal 
fusion polypeptide (MDYKDDDK) called flag (Kodak, Rochester, 
NY). Briefly, each construct was radiolabeled with either 0.2 uCi of 
L-[U-14C]leucine (>300 mCi/mmol; Amersham Corp., Arlington 
Heights, IL) or 40 uCi L-[35S]methionine (> 1000 Ci/mmol) and trans-
lated in vitro by the TNT T7 coupled reticulocyte lysate system ac-
cording to the manufacturer's protocol (Promega Corp., Madison, 
WI). 
2.3. Immunoprecipitation experiments 
Five microliters of each of the two different in vitro translated 
dystrophin fragments to be tested were incubated on ice for 2 h 
with 40 ul of TBST buffer (10 mM Tris-HCl (pH 8.0), 0.1% Tween 
20, 150 mM NaCl). Antibody directed against one of the two dystro-
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phin fragments (1.5-10 ug) was then added to the mixture and incu-
bated on ice for another hour. The complex was precipitated by add-
ing 50 u.1 of 50% protein G-Sepharose (Sigma Chem. Co., St. Louis, 
MO) and incubating on ice for another 30 min. The mixture was then 
pelleted at lOOOOXg for 2 min at room temperature, washed 3 times 
with 1 ml of TBST buffer and analyzed on 8.5% SDS-PAGE gel as 
previously described [16]. All gels were exposed to a storage phosphor 
plate after being fixed and dried. The plate was scanned by a Phos-
phorlmager (Molecular Dynamics, Sunnyvale, CA) and analyzed by 
the ImageQuant software (Molecular Dynamics). 
The immunoprecipitation experiments were also carried out under 
different salt concentrations (150-500 mM), detergent compositions, 
(1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) and pH (7.4 
and 8.0). They all produced results similar to those obtained with 
TBST buffer. 
2.4. Trypsin digestion of in vitro translated dystrophin fragments 
In vitro translated [35S]methionine-labeled dystrophin fragments 
were immunoprecipitated by the appropriate antibody as described 
above. The immunoprecipitated dystrophin fragment was then incu-
bated with trypsin in an enzyme to protein ratio of approximately 
1:50 in incubation buffer (100 mM Tris-HCl (pH 8.0), 125 mM su-
crose, 2.5 mM HEPES) at 37°C for different time intervals and was 
analyzed on 12% SDS-PAGE gel. 
2.5. Blot overlay experiments 
In vitro translated dystrophin fragments (or human skeletal muscle 
homogenates) were separated by 8.5% or 10% SDS-PAGE gel and 
transferred overnight onto nitrocellulose membrane (constant current 
of 70 mA at room temperature). The human skeletal muscle homog-
enates were isolated according to method described previously [17]. 
The membrane was blocked at 4°C for 2 h in blocking buffer (0.1% 
gelatin, 5% bovine serum albumin, 0.1% Tween 20 in 1 XPBS, pH 7.5). 
It was then incubated with the in vitro translated [36S]methionine-
labeled dystrophin fragment in overlay buffer (150 mM NaCl, 20 
mM HEPES, 2 mM MgCl2, 5% bovine serum albumin, pH 7.5) at 
a concentration of 10 JJ.1 of translation mix per milliliter of overlay 
buffer [18]. The incubation was carried out overnight at 4°C. After 
five washes with 20 ml of overlay buffer, the blot was dried briefly and 
exposed to a storage phosphor plate and analyzed by the Phosphor-
Imager as described above. 
3. Results 
3.1. Expression of dystrophin fragments in vitro 
The in vitro expression of dystrophin has been shown to be 
limited to 150 kDa [16]. Expression of larger size products 
often results in multiple smaller fragments, presumably due 
to degradation and inefficient translation. To circumvent 
this problem, it became necessary to break down dystrophin 
into smaller sizes. Eight overlapping constructs were designed 
to encompass the entire dystrophin sequence (Table 1). Each 
clone encoded a domain of dystrophin as predicted by its 
secondary structure [7]. The dystrophin fragments were de-
signed to be different sizes so that they could be separated 
and distinguished by SDS-PAGE gels. 
Upon in vitro translation, each dystrophin sub-fragment 
expressed a polypeptide of predicted size with no significant 
degradation ( < 5%) as judged by SDS-PAGE gel and Phos-
phorlmager (Fig. 1). In both Western blots and immunopre-
cipitation assay, each dystrophin fragment was only recog-
nized by the antibodies specific to the domain it encoded 
(data not shown). In addition, most fragments produced a 
pattern of proteolytic cleavage similar to native dystrophin 
after trypsin digestion (Fig. 2) [19]. All these results suggested 
that the in vitro translated dystrophin fragments were stable 
and adopted a conformation similar to the native full-length 
dystrophin. 
Table 1 
Construction of 
* C o n s t r i 
N 8 2 8 
H 1 - H 2 
H 2 - R 1 1 
R 1 2 - H 3 
R 7 - R 1 5 
R 1 9 - H 4 
C 2 3 2 1 
C 2 9 7 9 
I C t 
GTG 
expression vectors 
*PCR P r i m e r s 
cccaGtaccATGCTTTGGTGOGAAGAAGTAGAG 
GATcTcGaatcaATACTCCAGCCAGTTAAG 
GAAGgtaccATGTTGCCAAGGCCACCT 
TTactAgTCCACAGTAATCTGCCT 
ATTTCcatGGCTGTCACCACCACTCAG 
TTTCTaaAACTGTTGCTTTCTTTOTGT 
CAACccaTGGAGAAATGOTTGAAATTG 
AGCAGGTACCTaCAACATCAAGGAAGA 
AAATccATGGCTGAAGTTGATGTTTTT 
AGTGTGAATTcGTc:aAAAGTTGAGTCT 
GAAAccatgGCTCAAATAAAAGACCTT 
GTCTc taGAGTTTCATGGCAGTCCT 
ATTGCCataaAAATAAAAGACfTTGGGCAG 
ATGTAGaaTTCTTATAACTTTTTTGT 
acttccacCAtGGCACTGCGAGGAGAAATT 
GAatcGACTTCCTACATTGTGTCCTCTCTCATTGGCT 
C l o n i n a 
S i t e s 
K p n I / X h o I 
K p n I / S p e l 
N c o l / X b a l 
N c o l / K p n l 
N c o i / E c o R I 
N c o l / X b a l 
N c o i / E c o R I 
N c o I / B a m H T 
^ D o m a i n 
N - t e r m i n u s 
+ r e p e a t 1 -
h i n g e 1 - 2 
h i n g e 2 -
r e p e a t 1 1 
r e p e a t 1 2 -
h i n g e 3 
r e p e a t 7 -
r e p e a t 1 5 
r e p e a t 1 9 -
h i n g e 4 
r e p e a t 1 9 -
C - t e r m i n u s 
r e p e a t 2 4 -
C - t e r m i n u s 
^ E x p r e s s e d D v s t r o D h i n 
S e a u e n c e 
M G T ( d y s l - 8 2 8 ) 
-4 
M G T ( d y s 2 5 3 ~ 7 1 7 ) 
M ( d y s 6 6 8 - 1 5 6 6 ) 
M ( d y s l 5 6 7 - 2 4 6 7 ) 
d y s l 0 6 4 - 1 9 7 1 
M ( d y s 2 3 1 8 - 3 1 1 2 ) 
M ( d y s 2 3 1 9 - 3 6 8 5 ) 
M ( d y s 2 9 8 0 - 3 6 8 5 ) 
N o . Of 
R e s i d u e s 
8 2 8 
4 6 5 
8 9 9 
9 0 1 
9 0 8 
7 9 5 
1 3 6 7 
7 0 6 
P r e d i c 
S i z i 
9 5 . 7 
5 3 . 6 
1 0 4 , 2 
1 0 4 . 8 
1 0 5 . 6 
9 2 . 4 
1 5 7 . 5 
8 0 . 4 
r t e d 
kD 
kD 
kD 
kD 
kD 
kD 
kD 
kD 
"Each construct also has a variant version with a N-terminal flag fusion polypeptide (MDYKDDDKGS). 
bPrimers are written in the conventional 5 '-3' direction, the upper one being the forward primer, the lower one being the reverse primer. Nu-
cleotides in capital letter represent the wild-type dystrophin sequence. Nucleotides in small letter indicate a change from the wild-type sequence 
in order to create a restriction site compatible with the vectors. The created restriction sites were underlined. 
cDomains of dystrophin were predicted from secondary structure according to Koenig [7]. 
dSingle letter amino acid symbols are used. Amino acid numbers for human dystrophin was from Koenig [7]. 
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Fig. 1. In vitro translation of dystrophin fragments. Diagram depicts secondary structure of dystrophin. N, N-terminal actin-binding domain; 
Cys, cysteine-rich domain; C, unique C-terminal domain. The rod domain is represented by squares (hinge region, H) and circles (repeat unit 
1-24). The solid bars denote the in vitro translated dystrophin fragments. All reactions were labeled with L-[U-14C]leucine according to Section 
2. Lane 1: N828; lane 2: H1-H2; lane 3: H2-R11; lane 4: R12-H3; lane 5: R7-R15; lane 6: R19-H4; lane 7: C2321; lane 8: C2979; lane 
9: 14C-methylated high molecular mass standards (Amersham Corp.). 
3.2. Dystrophin fragments did not interact with each other in 
co-immunoprecipitation assay 
Before we began the systematic screening of dystrophin 
fragments for specific interactions, we first tested the validity 
of using the in vitro translated dystrophin fragments by dem-
onstrating that in vitro translated spectrin fragments can as-
sociate with each other in co-immunoprecipitation assay pro-
viding that they contain the dimerization domains. Clones 
Pi_4 encodes the N-terminal domain and the first three repeat 
units of P-spectrin (100 kDa) and clone 049-22 encodes the last 
three repeat units and the C-terminal domain of a-spectrin (57 
kDa). Together, they mediate the interaction between P- and 
a-spectrin [20,21]. As shown in Fig. 3A, an antibody specific 
to P-spectrin was able to precipitate both Pi_4 and 0:19-22 
(Fig. 3A, lane 5). In contrast, when assayed with the same 
antibody, Pi_4 failed to co-precipitate a 049-22 mutant that 
has two small in-frame deletions which abolished the inter-
chain binding activity (Fig. 3A, lane 7). All three spectrin 
clones were in vitro translated into a single product of ex-
pected size (Fig. 3A, lanes 1-3). No protein was precipitated 
in the absence of antibody (Fig. 3A, lanes 4 and 6), thus 
documenting the specific in vitro co-immunoprecipitation of 
the spectrin chains. Pi-Syntrophin, a dystrophin associated 
protein, was also demonstrated by the same assay to interact 
with the C-terminal dystrophin fragment (data not shown). 
This result was consistent with findings by our group [16] 
and others using different methods [22]. 
Given the fact that the end termini of spectrin plays an 
important role in its dimerization, the terminal domains of 
dystrophin were tested first. Clone N828 encodes the N-ter-
minal actin binding sites and the first four tandemly repeating 
units of dystrophin. Clone C2321 encodes the last six repeat 
Fig. 2. Trypsin digestion of in vitro translated dystrophin fragments. In vitro translated 35S-labeled dystrophin fragments were digested with 
trypsin for different intervals of time (0-45 min) according to Section 2. A: N828. B: R19-H4. In both examples, correct folding of the frag-
ment was characterized by the presence of proteolytic resistant subfragments of lower molecular mass that were similar to the trypsin digest of 
native full-length dystrophin [19]. 
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Fig. 3. A: Interaction between Pi_4 spectrin and ai9_22 spectrin in co-immunoprecipitation assay. In vitro translated product of pi_4 spectrin 
fragment (lane 1), 0119-22 spectrin fragment (lane 2), 0(19-22 mutant spectrin fragment (lane 3). p\_4 was incubated with 0:19-22 in lanes 4 and 5. 
Similarly, Pi_4 was incubated with 0:19-22 mutant in lanes 6 and 7. The absence or presence of antibody was indicated by (—) or (+), respec-
tively. Lane M: 14C-Methylated high molecular mass standards. B: Terminal domains of dystrophin do not interact with each other in co-im-
munoprecipitation assay. Lanes 1-4: 14C-Labeled N828 and C2321 were incubated in the presence (+) or absence (—) of dys 2 (Novacastra, 
UK), an antibody directed against the C-terminus of dystrophin (lane 2) and dys 3 (Novacastra), an antibody directed against the N-terminus 
of dystrophin (lane 3). Lane 1: Supernatant(s) from both N828 and C2321. Lanes 5-7: 14C-Labeled C2321 was incubated with its unlabeled 
flag version, F2321 in the presence (+) or absence (—) of an anti-flag antibody, M2. Lanes 7-9: 14C-Labeled N828 was incubated with its unla-
beled flag version, F828 in the presence (+) or absence (—) of the M2 antibody. 
units and the entire C-terminus of dystrophin (Table 1). When 
both 14C-labeled dystrophin fragments were incubated togeth-
er with an antibody directed against the C-terminal dystro-
phin (dys 2), C2321 failed to precipitate N828 (Fig. 3B, lane 
2). When the assay was reversed, N828 did not co-precipitate 
C2321 using a N-terminal specific dystrophin antibody (dys 3) 
as the detector (Fig. 3B, lane 3). Neither dystrophin fragments 
were precipitated in the absence of antibody (Fig. 3B, lane 4). 
Interaction between the same terminal domains of dystro-
phin was then tested. In order to detect self-association of the 
same dystrophin fragment, a variant version of the original 
construct was designed. The resulting construct, F2321, en-
codes the exact dystrophin sequence as C2321, except with 
the addition of a flag-tag (MDYKDDDK) fusion polypeptide 
at its N-terminus which is recognized by a unique anti-flag 
antibody, M2 (Kodak, Rochester, NY). As shown in Fig. 3B, 
the unlabeled F2321 did not precipitate the 14C-labeled C2321 
with the anti-flag antibody (Fig. 3B, lane 6). The radiolabeled 
C2321 remained in the supernatant (Fig. 3B, lane 5) and was 
not precipitated in the absence of M2 antibody (Fig. 3B, lane 
7). Similarly, no interaction was detected between the two N-
terminal dystrophin fragments (Fig. 3B, lanes 8-10). 
With the absence of evidence for interactions between the 
end-terminal domains, six additional overlapping clones were 
engineered to covered the entire oc-helical rod domain of dys-
trophin (Table 1). Each of the eight dystrophin fragments was 
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Fig. 4. In vitro translated dystrophin fragments do not interact with each other in blot overlay assay. A: [35S]Methionine-labeled Bi_4 spectrin 
was used as a probe. Lane 1: Pi_4 spectrin; lane 2: ai9_22 spectrin; lane 3: mutant 0119-22 spectrin. B; [
35S]Methionine-labeled a-actinin 2 was 
used as a probe. Lane 1: N-terminal truncated a-actinin 2; lane 2: a-actinin 2; lane 3: a-actinin 3. C: [36S]Methionine-labeled Pi-syntrophin 
was used as a probe. Lane 1: Mutant aig_22 spectrin; lane 2: ai9_22 spectrin; lane 3: Pi-syntrophin; lane 4: C2979; lane 5: R19-H4; lane 6: 
R12-H3; lane 7: R7-R15; lane 8: H2-R11; lane 9: N828; lane M: 14C-methylated high molecular mass standards. Note that Pi-syntrophin 
only bound to C2979 (lane 4). The result is consistent with the immunoprecipitation data in which among all the dystrophin fragments, only 
the C-terminus was able to interact with pi-syntrophin (data not shown). D: [35S]Methionine-labeled H2-R11 was used as a probe. The lanes 
were in same order as (C). Replica of the membrane were prepared and each membrane was overlaid with the other in vitro translated 35S-la-
beled dystrophin fragments according to Section 2. 
then tested for its ability to co-precipitate with each other, 
including itself. A total of 35 combinations were analyzed 
but no interaction was detected with any combination (data 
not shown). 
3.3. Absence of dystrophin self-association in blot overlay 
assays 
Blot overlay was subsequently used to investigate the po-
tential binding between dystrophin fragments. Different in 
vitro translated dystrophin fragments were separated by 
SDS-PAGE gel and transferred to nitrocellulose membrane. 
The membrane was then blocked and incubated with the in 
vitro translated 35S-labeled dystrophin fragments according to 
Section 2. To ensure all the dystrophin fragments were prop-
erly translated, the membrane was prepared in replica and 
analyzed by Western blot (data not shown). When 35S-labeled 
pi_4 spectrin was used as a probe, it only bound to the wild-
type (Xi9_22 spectrin (Fig. 4A, lane 2) but not to itself (Fig. 4A, 
lane 1) or the mutant 0Cig_22 spectrin (Fig. 4A, lane 3). Sim-
ilarly, a-actinin 2 bound to both a-actinin 2 and 3 isoforms, 
as well as a N-terminal truncated a-actinin 2 (Fig. 4B). 35S-
Labeled Pi-syntrophin was also shown to bind to the C-ter-
minal dystrophin fragment, C2979 (Fig. 4C, lane 4). However, 
none of the dystrophin fragments were able to bind to the 
membrane (Fig. 4D). 
In addition, we also tested the ability of the in vitro trans-
lated dystrophin fragments to interact with full-length native 
dystrophin. The same set of in vitro translated 35S-labeled 
dystrophin fragments were overlaid on nitrocellulose mem-
branes containing tissue homogenates prepared from human 
skeletal muscle. Western blots, using dystrophin specific anti-
bodies, showed the full-length dystrophin was intact (Fig. 5, 
lane 1). When 35S-labeled Pi-syntrophin was used as a probe, 
it bound to the full-length dystrophin as expected (Fig. 5, lane 
2). Similarly, when either Pi_4 spectrin (Fig. 5, lane 6) or a-
actinin 2 (Fig. 5, lane 7) were used as probes, they bound to 
spectrin and a-actinin at the expected size of 240 kDa (arrow) 
and 100 kDa (double arrow) respectively. Again, none of the 
dystrophin fragments were able to bind to the full-length dys-
trophin (Fig. 5, lanes 3-5). 
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Fig. 5. In vitro translated dystrophin fragments do not interact with full-length dystrophin in blot overlay assay. Fifty micrograms of the 
muscle homogenate was loaded on 8.5% or 10% SDS-PAGE gel and transferred to nitrocellulose membrane. Replica of membrane were pre-
pared and each membrane was overlaid with the in vitro translated 35S-labeled dystrophin fragments according to Section 2. Pi-syntrophin, 
Pi_4 spectrin and cc-actinin 2 probe were used as positive controls. Lane 1: Western blot of the muscle extract using a C-terminal specific dys-
trophin antibody, dys 2. Lanes 2-7: Membrane was overlaid with different 35S-labeled probes: Pi-syntrophin (lane 2); N828 (lane 3); H2-R11 
(lane 4); R12-H3 (lane 5); Pi_4 spectrin (lane 6); a-actinin 2 (lane 7). 
4. Discussion 
In summary, we expressed fragments of dystrophin that are 
about one-fourth of its full length by an in vitro translation 
system and tested their ability to interact with each other by 
immunoprecipitation and blot overlay experiments. Neither 
assay was able to identify any interaction between the in vitro 
translated dystrophin fragments (Table 2). In addition, none 
of the fragments interacted with the full-length native dystro-
phin from human muscle tissue homogenate in blot overlay 
assays. In contrast, when we expressed a-actinin or spectrin 
fragments that were homologous to the dystrophin fragments, 
we clearly showed a specific interaction between different iso-
forms of a-actinin as well as between spectrin fragments that 
contain the interchain binding sites. Collectively, these results 
suggested that dystrophin behaves quite differently in vitro 
from spectrin and a-actinin despite their significant homol-
ogy. In support of this view, conformation and phasing anal-
yses of the spectrin-like repeats in the dystrophin rod domain 
indicated an irregular and less rigid structure than spectrin 
[23,24]. Recently, Kahana et al. have also suggested that dys-
trophin might exist as a monomer based on the physical prop-
erties of the rod domain [25]. 
While both dystrophin monomers and dimers have been 
reported by electron microscopy [13-15], our findings sup-
ported the existence of dystrophin as a monomer. In a sepa-
rate experiment, immunogold-labeling of muscle tissue with a 
C-terminal dystrophin antibody always localized dystrophin 
immediately beneath the muscle membrane [26] while an anti-
body raised against the N-terminal portion of the rod domain 
localized dystrophin at 15-20 nm internal to the sarcolemma 
[27]. Since neither antibody label showed any difference in 
relative distance to the membrane or periodicity in the distri-
bution of the immunogold-label (which is approximately 125 
nm, the predicted rod length of dystrophin), this finding was 
inconsistent with the current model of an anti-parallel dystro-
phin dimer but was supportive of a dystrophin monomer. 
(However, it did not rule out the possibility of a parallel 
dystrophin dimer.) In addition, there are examples of patients 
with large internal in-frame deletion in the rod domain but 
Table 2 
Summary of all possible combinations of interactions tested 
N828 H1-H2 H2-R11 R12-H3 R7-R15 R19-H4 C2321 C2979 Pi-syn pi_4 ai9_22 a-actinin 
N828 
H1-H2 
H2-R11 
R12-H3 
R7-R15 
R19-H4 
C2321 
C2979 
pi-syn 
Pl-4 
OC19-22 
a-actinin 
ND ND ND 
ND ND 
ND ND 
— + ND 
ND 
+ 
Thirty-five different combinations from eight dystrophin fragments were tested for their ability to interact with each other. P^syntrophin, p!_4 
spectrin, aig_22 spectrin and a-actinin were also included as positive controls. The presence or absence of interaction was indicated by + or —, 
respectively. ND, not determined. Note that the H1-H2 was not tested for its self-association because the domains encoded by N828 already 
included H1-H2. 
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nevertheless have very mild symptoms [28,29]. Such deletions 
are likely to be very disruptive had dystrophin existed as a 
dimer. Recently, Beckman has also argued against a dystro-
phin dimer because of the lack of dominant-negative effects in 
transgenic mice overexpressing truncated dystrophin [30]. 
Although our results suggested that dystrophin did not di-
merize in vitro, we cannot rule out the possibility that dystro-
phin exists as a dimer in vivo. If this is the case, the interac-
tion between dystrophin is likely to be weak as suggested by 
Pons and Fabbrizio who demonstrated that the majority of 
dystrophin prepared from chicken gizzard muscle and cardiac 
muscle was in monomeric form under electron microscopy 
[13,14,31]. On the other hand, it is possible that dystrophin 
might exist as a heterodimer with some unknown isoforms. 
Other factors, such as accessory proteins, phosphorylation or 
the specific conformation adopted by the full-length native 
dystrophin could also affect its self-association properties. 
Meanwhile, when we performed in vivo chemical crosslinking 
of dystrophin from mouse C2C12 myotubes, it often resulted 
in a large aggregate that was not interpretable, even after 
limited trypsin digestion (data not shown). 
While we cannot unequivocally prove that dystrophin is a 
monomer, our results provide the strongest evidence today 
that dystrophin by itself, in the absence of accessory proteins, 
does not associate with itself in vitro. The current hypothesis 
that dystrophin is a dimer, which is based solely on its anal-
ogy to spectrin, needs to be re-examined more closely. Further 
studies, such as chemical crosslinking or sedimentation equi-
librium analysis of in vivo purified dystrophin, should provide 
valuable information on the 'true state' of dystrophin. 
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